[
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What is the main focus of the study conducted by Slattery et al.?\nAnswer: The study investigates whether a family history of breast cancer affects survival outcomes among women diagnosed with the disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What data sources were utilized in the study?\nAnswer: The study utilized the Utah Cancer Registry and the Utah Population Database, which provided detailed genealogy data from Mormon pioneer families.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: How many women were included in the study population?\nAnswer: The analysis focused on 3,578 women diagnosed with a first primary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What were the key findings regarding family history and survival?\nAnswer: Overall, women with a family history of breast cancer had poorer survival compared to those without such a history, particularly younger women diagnosed at age 50 or younger.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What statistical methods were used to analyze survival time?\nAnswer: Kaplan\u2013Meier methods were used to estimate survival time, and Cox proportional hazards models were employed to calculate hazard rate ratios (HRRs).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What was the hazard rate ratio (HRR) associated with having a mother with breast cancer?\nAnswer: Having a mother with breast cancer was associated with an HRR of approximately 1.55.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: Did the study find any protective effects of family history in older women?\nAnswer: Yes, certain family history indicators, such as having a sister with breast cancer, did not show a consistent association with poorer survival and might even suggest a slight protective effect among older women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What conclusion did the authors draw regarding family history and breast cancer survival?\nAnswer: The study concluded that a positive family history of breast cancer is associated with poorer survival among women diagnosed with breast cancer, especially in those diagnosed at a younger age.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What limitations did the authors acknowledge in their study?\nAnswer: The study population comes from Utah, which might limit generalizability, and there may be incomplete family history if relatives moved out of state.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "c100d1fb79164364bd30cc77ce4aa805",
            "source": "Slattery-SurvivalamongWomen-1993",
            "main_category": "Slattery"
        },
        "page_content": "Question: What implications do the findings have for breast cancer research and treatment?\nAnswer: The findings suggest that family history may capture underlying genetic or environmental factors affecting cancer risk and survival, highlighting the importance of considering family history in prognostic assessments and follow-up care.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What is the main focus of the study conducted by Gho et al.?\nAnswer: The study investigates the self-reported side effects experienced by breast cancer patients following treatment, examining their incidence, associations with patient characteristics, and the influence of exercise.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What were the primary objectives of the study?\nAnswer: The primary objectives were to quantify the incidence of various side effects reported by breast cancer survivors, explore associations between these side effects and patient characteristics, and determine the influence of current exercise levels on the severity of side effects.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: How many participants were involved in the study and what was their demographic?\nAnswer: The study involved 432 breast cancer patients who were over 18 years old and had a history of breast cancer, recruited from the Breast Cancer Network Australia and Cancer Councils of Victoria and Western Australia.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What method was used to collect data on exercise levels?\nAnswer: Current exercise levels were assessed using the Global Physical Activity Questionnaire Version 2 (GPAQ2), which classified physical activity into 'sufficiently active' versus 'insufficiently active.'",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What were some common side effects reported by participants?\nAnswer: Common side effects included hot flushes, sleep disorders, aching muscles, fatigue, and weight gain.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: How did the type of surgery affect the reported side effects?\nAnswer: Women who underwent a lumpectomy reported fewer side effects, such as less aching muscle, hot flushes, and weight gain, compared to those who had a mastectomy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What was the relationship between exercise levels and side effects?\nAnswer: Sufficient levels of exercise were associated with a reduced likelihood of experiencing several side effects, including lower odds of weight gain and shoulder limitations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What conclusions did the study reach regarding the impact of exercise on quality of life?\nAnswer: The study concluded that sufficient levels of exercise are consistently associated with a reduced incidence and severity of several side effects, highlighting the potential for exercise-based interventions to improve post-treatment quality of life among breast cancer survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What implications for practice were suggested for healthcare providers?\nAnswer: Healthcare providers are encouraged to integrate exercise programs into post-treatment care to help mitigate negative side effects experienced by breast cancer survivors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "d5df5d25ed5840f29a42b8cd7cf9751e",
            "source": "Gho-Selfreportedsideeffects-2013",
            "main_category": "Gho"
        },
        "page_content": "Question: What further research is suggested by the authors?\nAnswer: Further research is needed to explore causal relationships and determine the optimal types and intensities of exercise that yield the most benefit for reducing treatment-related side effects.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the purpose of the WHO annex on anti-cancer medicines for breast cancer?\nAnswer: The purpose of the WHO annex is to provide guidance on the selection and use of anti-cancer medicines for breast cancer treatment and to detail the medicines included on the WHO Model List of Essential Medicines 2021.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the four distinct subtypes of breast cancer recognized in the document?\nAnswer: The four distinct subtypes of breast cancer recognized are Luminal A, Luminal B, Triple-negative, and HER2-positive.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the primary treatment for Hormone-Receptor Positive (ER+) Breast Cancer?\nAnswer: The primary treatment for Hormone-Receptor Positive (ER+) Breast Cancer is endocrine (hormone) therapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the mainstay treatment for Triple-Negative Breast Cancer?\nAnswer: Chemotherapy is the mainstay treatment for Triple-Negative Breast Cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What are some examples of standard chemotherapy regimens for breast cancer mentioned in the document?\nAnswer: Examples of standard chemotherapy regimens include TC (docetaxel and cyclophosphamide), AC-T (doxorubicin and cyclophosphamide followed by paclitaxel), CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), and FAC/FEC (5-fluorouracil, doxorubicin, and cyclophosphamide).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What supportive care measures are emphasized in the document for breast cancer treatment?\nAnswer: Supportive care measures include antiemetics, growth factors, bone-modifying agents, and potentially anti-depressants to manage side effects and maintain patient quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the significance of the WHO Model List of Essential Medicines in breast cancer treatment?\nAnswer: The WHO Model List of Essential Medicines ensures that the most important anti-cancer and supportive medications are available globally, even in low-resource settings.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: How does the document suggest treatment may be adapted for individual patients?\nAnswer: Treatment may be modified based on individual patient factors such as toxicity profile, comorbidities, and cost considerations, especially regarding high-cost targeted therapies like trastuzumab.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "d18845ff8f944d77a3b17a569e0d20b9",
            "source": "Organization-Annex-2023",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the conclusion of the WHO annex regarding breast cancer treatment?\nAnswer: The conclusion emphasizes the importance of integrating evidence-based chemotherapy, endocrine therapy, and targeted treatments with appropriate supportive care to ensure effective and feasible treatment protocols.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What is the main focus of the editorial by Silvia Franceschi?\nAnswer: The editorial examines the relationships between breast size, breast reduction surgery, and breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: How might large breast size contribute to breast cancer risk according to the document?\nAnswer: Large breast size may result from increased cell proliferation early in life, leading to a higher number of proliferating ductal stem cells in adulthood, which is central to cancer development.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What factors are believed to promote enhanced cell proliferation in early life?\nAnswer: Elevated estrogen exposure in utero and high energy intake during childhood and adolescence are believed to promote enhanced cell proliferation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What did population studies find regarding breast size and breast cancer incidence among Asian women?\nAnswer: Population studies noted that Asian women, who typically have smaller breasts, tend to have lower breast cancer incidence compared to Western women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What was the outcome of studies using bra cup size as a measure of breast volume in relation to breast cancer risk?\nAnswer: Case-control studies using bra cup size have not consistently supported a strong association with breast cancer risk after adjusting for body mass index.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What did the study by Boice et al. reveal about breast reduction surgery and breast cancer risk?\nAnswer: The study found that among women who underwent breast reduction surgery, only 29 cases of breast cancer were observed versus 53.9 expected, indicating a standardized incidence ratio of 0.5.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What are some methodological challenges mentioned in the document regarding studies on breast cancer risk?\nAnswer: Challenges include calculating the expected number of breast cancers in women with partially removed breast tissue and the influence of subtle alterations in the microenvironment on cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: How is breast reduction surgery conceptualized as a preventive strategy?\nAnswer: Breast reduction surgery is seen as a dual approach that removes excess, potentially cancer-prone tissue and may facilitate the early detection and removal of preneoplastic lesions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What reassurance does the editorial provide to women considering breast reduction surgery?\nAnswer: The findings suggest that breast reduction surgery can contribute to cancer prevention without entirely eliminating the need for regular screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "7f8f9afd57bc4c118cd3116e6e9b74e6",
            "source": "Franceschi-BreastSizeBreast-1997",
            "main_category": "Franceschi"
        },
        "page_content": "Question: What is the conclusion regarding the relationship between breast reduction surgery and breast cancer risk?\nAnswer: Breast reduction surgery may lower breast cancer risk by removing preneoplastic lesions and reducing overall breast tissue susceptible to malignant transformation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What is the main focus of the study conducted by Slattery, Berry, and Kerber?\nAnswer: The study investigates whether the survival of women diagnosed with breast cancer is influenced by their family history of the disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What data source was used in the study to analyze family history and breast cancer survival?\nAnswer: The study used data from the Utah Population Database, which links genealogy, cancer registry, and vital statistics data.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: How many women were included in the study population?\nAnswer: The analysis included 4,083 women diagnosed with a first primary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What statistical methods were employed to analyze survival outcomes?\nAnswer: Survival analysis was conducted using Kaplan\u2013Meier estimates and Cox proportional hazards models.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What key finding was reported regarding women with a family history of breast cancer?\nAnswer: Women with a family history of breast cancer tended to have shorter median survival compared to those without such a history.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: Which group of women showed the most pronounced effect of family history on survival?\nAnswer: The effect of family history was most pronounced in women diagnosed at or before age 50.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What limitations did the study acknowledge?\nAnswer: The study acknowledged limitations such as incomplete family history data, possible misclassification, and the population being potentially unrepresentative of all U.S. populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What implications do the study's findings have for breast cancer prognosis?\nAnswer: The findings underscore the importance of considering detailed family history when evaluating prognosis in breast cancer patients and suggest the need for tailored treatment and surveillance strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "a458034597364ae5bffbf764432f5946",
            "source": "Thomas-ORIGINALRESEARCHMens-2010",
            "main_category": "Thomas"
        },
        "page_content": "Question: What conclusion did the authors reach regarding family history and breast cancer survival?\nAnswer: The study concluded that certain aspects of family history, especially having a mother with breast cancer or a large number of affected female relatives, are associated with poorer survival among women diagnosed with breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What is lymphedema and how is it related to breast cancer treatment?\nAnswer: Lymphedema is a condition that arises from damage to or removal of lymph nodes during breast cancer treatment, leading to impaired lymphatic drainage and fluid accumulation.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are the two main types of lymphedema based on onset?\nAnswer: The two main types of lymphedema are acute lymphedema, which occurs shortly after surgery, and chronic lymphedema, which develops if acute lymphedema is untreated.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are the clinical manifestations of acute lymphedema?\nAnswer: Acute lymphedema is characterized by pitting edema, swelling, tightness, and a feeling of heaviness in the affected limb, often resolving within weeks.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What factors increase the risk of developing lymphedema after breast cancer treatment?\nAnswer: Risk factors include surgical procedures like axillary node dissection, radiation therapy, injuries, infections, and lifestyle factors such as air travel.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What preventive measures can be taken to minimize the risk of lymphedema?\nAnswer: Preventive measures include early identification, patient education, avoiding constrictive items, and taking precautions during activities like air travel.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are some management strategies for lymphedema?\nAnswer: Management strategies include Manual Lymph Drainage (MLD), compression therapy, gentle exercises, skin care, and advanced treatments like complete decongestive physiotherapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What role do nurses play in the management of lymphedema?\nAnswer: Nurses are responsible for assessment, patient education, advocacy for standardized care, and participation in research to improve treatment outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What is the significance of early detection of lymphedema in breast cancer survivors?\nAnswer: Early detection is crucial as it allows for timely intervention, which can prevent the progression of lymphedema and improve the quality of life for patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "f264f57985464d8a89304d506a2205e4",
            "source": "Davis-LymphedemaBreastCancer-2001",
            "main_category": "Davis"
        },
        "page_content": "Question: What are the implications of lymphedema for breast cancer survivors?\nAnswer: Lymphedema can lead to chronic symptoms, increased risk of infections, and may require ongoing management, impacting the survivor's quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What is the emotional impact of a breast cancer diagnosis?\nAnswer: A breast cancer diagnosis is typically anxiety-provoking and traumatic, often historically viewed as a 'death sentence.' Despite improved survival rates, patients and families experience high levels of distress, anxiety, and depression, especially in the early phases after diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: How does breast cancer epidemiology differ by age?\nAnswer: Breast cancer is the most common cancer in women, with risk increasing with age. Young women often face more aggressive disease, leading to higher risks of recurrence and mortality compared to older women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What role does social support play for breast cancer patients?\nAnswer: Social support is crucial for coping with a breast cancer diagnosis, encompassing emotional, informational, and instrumental dimensions. Strong support networks can alleviate psychological burdens.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What specific challenges do breast cancer patients face?\nAnswer: Breast cancer patients often experience significant emotional distress, body image issues, and impacts on relationships. Major depression prevalence ranges from 10% to 25%, particularly high during the first year after diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: How does breast cancer affect intimate partner dynamics?\nAnswer: The emotional challenges of breast cancer extend to intimate partners, with distress often mirrored between partners. Supportive relationships can mitigate anxiety and depression.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What are the implications for interventions and policy regarding breast cancer support?\nAnswer: Interventions should focus on enhancing spousal and family support, encouraging couple-focused counseling, and addressing both clinical and psychosocial needs of patients and their families.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What variations exist in social support outcomes for couples dealing with breast cancer?\nAnswer: While many couples cope effectively, some younger couples or those with poor communication may face greater risks for negative psychosocial outcomes. Social networks often contract post-diagnosis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "7e7fe21170464e0c98e987c33bdae3a7",
            "source": "ROY-BreastCancerSocial-2011",
            "main_category": "ROY"
        },
        "page_content": "Question: What is the conclusion regarding the impact of breast cancer on patients and their families?\nAnswer: Breast cancer affects physical health, mental well-being, body image, and relationships. Effective social support, especially from intimate partners, is vital in mitigating adverse effects, though many still experience significant distress.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e6ae89c31bf74e098c172eb87f39c404",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What is the main focus of Emily Waples' essay 'Emplotted Bodies'?\nAnswer: The essay explores how breast cancer is represented in contemporary feminist discourse, interweaving personal narrative with cultural analysis.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e6ae89c31bf74e098c172eb87f39c404",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: How does Waples' personal experience influence her analysis of breast cancer narratives?\nAnswer: Waples recounts her own experience with mastectomy, which frames her exploration of embodiment, identity, and the tensions between biological and socially constructed femininity.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e6ae89c31bf74e098c172eb87f39c404",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What critique does Waples offer regarding dominant breast cancer narratives?\nAnswer: She critiques the prevailing 'survivor' narrative for presenting a homogenized image that marginalizes diverse experiences, particularly those of younger women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e6ae89c31bf74e098c172eb87f39c404",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What distinction does Waples make between postfeminism and third-wave feminism?\nAnswer: Waples critiques postfeminism for its apolitical nature and presents third-wave feminism as a transformative approach that can reframe breast cancer narratives in an intersectional context.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e6ae89c31bf74e098c172eb87f39c404",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: How does Waples suggest breast cancer narratives should evolve?\nAnswer: She argues for narratives that acknowledge vulnerability and multiplicity, resisting established tropes and including the voices of young women facing aggressive breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e6ae89c31bf74e098c172eb87f39c404",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What role do digital platforms play in breast cancer narratives according to Waples?\nAnswer: Digital media provide alternative spaces for breast cancer narratives, allowing for more nuanced and diverse accounts that challenge sanitized survivor stories.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e6ae89c31bf74e098c172eb87f39c404",
            "source": "Waples-EmplottedBodiesBreast-2013",
            "main_category": "Waples"
        },
        "page_content": "Question: What is the conclusion of Waples' essay regarding feminist engagement with breast cancer narratives?\nAnswer: Waples calls for a rearticulation of breast cancer narratives that are inclusive, intersectional, and politically potent, reflecting the diverse realities of young women today.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What is the main focus of the study conducted by Elmore et al.?\nAnswer: The study investigates racial differences in the method of breast cancer detection, the timing of diagnosis and initiation of treatment, and the association of these differences with clinical outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What disparities exist in breast cancer outcomes between black and white women according to the study?\nAnswer: Black women experience later-stage diagnoses, shorter survival times, and higher mortality rates compared to white women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What were the methods used to collect data in the study?\nAnswer: Data were collected from medical records, the Connecticut State Tumor Registry, and the U.S. Census, focusing on detection methods, timing measures, and additional variables like demographic characteristics and clinical outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: How did the method of breast cancer detection differ between black and white women?\nAnswer: Black women were more likely to have their cancer detected after noticing a breast abnormality (61% vs. 33%) and less likely to be diagnosed through screening methods.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What was the median time from first abnormality to diagnosis for black women compared to white women?\nAnswer: The median time for black women was 74 days, while for white women it was 59 days.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What percentage of black women had not initiated treatment within 30 days of diagnosis?\nAnswer: 33% of black women had not initiated treatment within 30 days compared to 21% of white women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What are the implications of the study's findings for clinicians and policymakers?\nAnswer: The findings highlight the need to address barriers to prompt diagnostic evaluation and treatment among black women to reduce racial disparities in breast cancer outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "b14a6e87d7f241b6a991f14fea3e209f",
            "source": "Elmore-RacialInequitiesTiming-2005",
            "main_category": "Elmore"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Further studies are needed to explore cultural, systemic, and socioeconomic barriers that contribute to delays in care, and to develop comprehensive interventions to improve equity in cancer care.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What is the main focus of the study conducted by Goddard et al.?\nAnswer: The study examines the real-world uptake and use of HER2 testing among breast cancer patients and its impact on treatment decisions, specifically the use of trastuzumab.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What percentage of breast cancers exhibit HER2 gene amplification?\nAnswer: HER2 gene amplification occurs in approximately 18\u201320% of breast cancers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What is trastuzumab and why is it significant in breast cancer treatment?\nAnswer: Trastuzumab is an effective drug that targets HER2-positive cancers, and it is significant because it benefits patients with HER2-positive tumors, which are associated with aggressive tumor behavior and poorer outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: How did the uptake of HER2 testing change from 1998 to 2000?\nAnswer: The uptake of HER2 testing among patients with invasive breast cancer increased dramatically from 12% in 1998 to over 94% by 2000.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What was the treatment pattern for trastuzumab after 2004?\nAnswer: After 2004, trastuzumab use increased significantly, with 55% of women with invasive breast cancer and HER2 overexpression receiving the treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What methods were used for HER2 testing in the study?\nAnswer: The study used immunohistochemistry (IHC) as the primary test for HER2 evaluation initially, with fluorescence in situ hybridization (FISH) reserved for clarifying equivocal or positive IHC results.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What were the findings regarding the concordance between IHC and FISH test results?\nAnswer: Chart reviews indicated high concordance between IHC and FISH test results, although some discrepancies were noted, particularly in cases with equivocal IHC findings.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What implications does the study suggest for clinical practice and health systems?\nAnswer: The study suggests that accurate HER2 evaluation is crucial for optimizing treatment decisions and that integrated healthcare systems with robust electronic records can facilitate the effective implementation of advanced diagnostic tests.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "11e5f5fb37974fe3a622411d1fe5823f",
            "source": "Goddard-HER2EvaluationImpact-2012",
            "main_category": "Goddard"
        },
        "page_content": "Question: What future research directions does the study propose?\nAnswer: The study proposes further research in diverse settings to assess the generalizability of the findings and to explore long-term patient outcomes related to HER2-targeted therapies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What is the main focus of the report by Kotsopoulos and Narod?\nAnswer: The report explores the potential for dietary modification to reduce the risk of hereditary breast cancer in women carrying deleterious mutations in the BRCA1 or BRCA2 genes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What is the estimated lifetime risk of breast cancer for BRCA1 and BRCA2 mutation carriers?\nAnswer: The lifetime risk of breast cancer for BRCA1 and BRCA2 mutation carriers is estimated to be between 38% and 87%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: How do environmental and lifestyle factors influence cancer risk among BRCA mutation carriers?\nAnswer: Variability in cancer risk among carriers suggests that environmental and lifestyle factors, including diet, may modify cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What role does estrogen play in BRCA-associated carcinogenesis?\nAnswer: Estrogen-induced cell proliferation and DNA damage are central to breast carcinogenesis, and BRCA gene products are involved in DNA damage repair pathways.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What dietary components are proposed as potential chemopreventive agents?\nAnswer: Nutrients and phytochemicals such as diindolylmethane (DIM), indole-3-carbinol (I3C), lycopene, selenium, and green tea polyphenols are highlighted as candidate agents.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What are the proposed mechanisms by which dietary agents may reduce breast cancer risk?\nAnswer: Dietary agents may decrease oxidative DNA damage, enhance DNA repair capacity, and favorably modulate estrogen metabolism.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What challenges do researchers face in conducting prospective trials for dietary interventions in high-risk populations?\nAnswer: Prospective trials with breast cancer as an endpoint are challenging in high-risk populations, necessitating the identification and validation of intermediate biomarkers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What conclusions do Kotsopoulos and Narod draw regarding dietary intervention?\nAnswer: They conclude that while evidence is preliminary, dietary intervention holds promise as a complementary strategy for the prevention of hereditary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: What further research do the authors call for?\nAnswer: They call for research to identify and validate reliable biomarkers of DNA damage and repair, conduct well-designed studies distinguishing between carriers and non-carriers, and evaluate the effectiveness of specific dietary regimens.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "39a1e86514d044f4ac5cb246056a67ed",
            "source": "Kotsopoulos-BriefReportTowards-2005",
            "main_category": "Kotsopoulos"
        },
        "page_content": "Question: How might dietary prevention benefit high-risk women?\nAnswer: If proven effective, dietary prevention could provide high-risk women with a non-invasive, cost-effective means to lower their risk, complementing existing strategies like prophylactic surgery.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What are the 'invisible scars' referred to in the article?\nAnswer: The 'invisible scars' refer to the emotional, psychological, and social impacts of breast cancer treatments that extend beyond physical changes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: How does the article critique the dominant narratives of breast cancer survivorship?\nAnswer: The article critiques the dominant narratives by highlighting that they often portray survivors as courageous heroines, masking the ongoing struggles such as chronic pain, altered body image, and loss of femininity.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What emotional and psychological impacts do breast cancer treatments have on survivors?\nAnswer: Treatments can lead to depression, anxiety, and disrupted sexual identity, which are often not captured by biomedical assessments but are deeply felt in survivors' daily lives.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What role do gendered dimensions play in the experience of breast cancer treatment?\nAnswer: Cultural expectations about femininity and the significance of breasts to a woman's identity influence how survivors experience treatment side effects, leading to feelings of loss and diminished sexual desirability.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What does Porroche-Escudero suggest regarding medical authority and narratives?\nAnswer: Porroche-Escudero suggests that biomedical and mass media discourses often silence the 'invisible scars' by promoting overly optimistic recovery narratives, marginalizing the real challenges survivors face.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What implications does the article have for patient support in breast cancer treatment?\nAnswer: The article emphasizes the need to recognize invisible scars to develop holistic care practices that address emotional, psychological, and social needs, suggesting the integration of qualitative, patient-centered research into treatment evaluations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What methodological approach does the article use?\nAnswer: The article employs ethnographic insights and critical analysis of cultural narratives, referencing various scholarly works on survivorship, gendered body politics, and the social impact of cancer treatments.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "006e7c16515948a0bea5f645ba2b3b21",
            "source": "PorrocheEscudero-invisiblescarsbreast-2014",
            "main_category": "PorrocheEscudero"
        },
        "page_content": "Question: What conclusion does Porroche-Escudero reach regarding breast cancer survivorship?\nAnswer: Porroche-Escudero concludes that a broader understanding of survivorship is needed, one that acknowledges and addresses the 'invisible scars' to improve care quality and validate the complex realities of survivors' lives.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What is the main objective of the study conducted by Ogundiran et al.?\nAnswer: The main objective of the study is to investigate the relationship between body fat distribution and the risk of invasive breast cancer in Nigerian women, particularly focusing on central adiposity.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What methods were used to collect data in the study?\nAnswer: Data was collected through structured questionnaires administered by trained research nurses, capturing demographic, reproductive, and lifestyle information, along with anthropometric measurements following WHO MONICA guidelines.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What were the key findings regarding waist circumference and breast cancer risk?\nAnswer: Women in the highest quartile of waist circumference (90\u2013138 cm) had a significantly higher breast cancer risk, with an adjusted odds ratio (OR) of 2.39 compared to those in the lowest quartile (45\u201373 cm).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: How does hip circumference relate to breast cancer risk according to the study?\nAnswer: The study found an inverse association between hip circumference and breast cancer risk, with an adjusted OR of 0.36 for women with hip circumference greater than 108 cm compared to those with 54\u201392 cm.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What was the association between waist/hip ratio (WHR) and breast cancer risk?\nAnswer: A strong positive association was noted, with women in the highest quartile of WHR (>0.87) having an adjusted OR of 2.15 compared to those in the lowest quartile (<0.77).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What implications do the study's findings have for public health?\nAnswer: The findings highlight the importance of assessing fat distribution, not just overall obesity, when evaluating breast cancer risk, especially in populations with different body composition profiles.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What limitations were noted in the study?\nAnswer: The study's limitations include potential recall and measurement biases due to its case-control design, the indirect nature of waist and hip circumference measurements of visceral fat, and the generalizability of findings being specific to the Nigerian population.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "14d979c9196040bea60f38b4887c4f9f",
            "source": "Ogundiran-Bodyfatdistribution-2012",
            "main_category": "Ogundiran"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Future studies are needed to further elucidate the biological mechanisms behind the associations found and to explore the role of central adiposity in breast cancer across diverse populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the definition of early diagnosis in cancer?\nAnswer: Early diagnosis is defined as the early identification of cancer in patients who already present with symptoms or signs suggestive of cancer, focusing on detecting cancer at the earliest possible stage to improve survival and quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: How does early diagnosis differ from screening?\nAnswer: Early diagnosis targets individuals with symptoms, while screening aims to identify unrecognized cancer in an apparently healthy population through systematic testing.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the key differences in participant volume between early diagnosis and screening programs?\nAnswer: Early diagnosis involves a limited number of symptomatic individuals, whereas screening programs involve the entire target population, often with participation rates 50\u2013100 times higher.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the health system requirements for early diagnosis?\nAnswer: Early diagnosis requires facilities and human resources for prompt clinical evaluation, pathology, radiology, staging, and treatment access.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the process involved in early diagnosis?\nAnswer: The early diagnosis process includes increasing public awareness of cancer symptoms, ensuring rapid clinical evaluation and accurate diagnosis, and providing timely access to treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What are the potential benefits and harms of screening programs?\nAnswer: Potential benefits of screening include reduced disease incidence and earlier diagnosis, while harms may include overdiagnosis, psychological distress, and complications from further testing.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What impact does early diagnosis have on cancer outcomes and mortality?\nAnswer: Early diagnosis linked to prompt treatment leads to earlier stage presentation and reduced cancer mortality, as evidenced by historical data showing declines in breast cancer mortality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What recommendations are made for integrating early diagnosis into cancer control?\nAnswer: Early diagnosis should be an integral part of comprehensive cancer control programs, ensuring adequate capacity for diagnosis and treatment before introducing population-wide screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What is the strategic importance of strengthening early diagnosis systems?\nAnswer: Strengthening early diagnosis systems is critical to improving cancer outcomes, especially in resource-limited settings, and is a prerequisite for effective screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "972612a90ea947f097c3a5f0ceb3f822",
            "source": "Organization-UNDERSTANDINGEARLYDIAGNOSIS-2017",
            "main_category": "Organization"
        },
        "page_content": "Question: What next steps are suggested for countries regarding early diagnosis and screening services?\nAnswer: Countries should perform comprehensive situation analyses to assess current capacity, identify barriers, and guide the implementation or expansion of early diagnosis and screening services.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is the primary goal of evolving breast cancer treatment strategies?\nAnswer: The primary goal remains improved survival, with an increasing emphasis on reducing treatment morbidity and enhancing quality of life.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: How effective is prophylactic mastectomy in reducing breast cancer risk for high-risk women?\nAnswer: Prophylactic mastectomy has been shown to reduce breast cancer risk by approximately 90% in high-risk women, including those with BRCA1 and BRCA2 mutations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What are some strategies to lower breast cancer risk in high-risk populations?\nAnswer: Strategies include performing oophorectomy to reduce estrogen exposure and using tamoxifen, which appears to lower breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is sentinel node biopsy and its significance in breast cancer treatment?\nAnswer: Sentinel node biopsy is a less invasive technique for axillary staging with high identification rates (over 90%) and a false-negative rate of less than 5%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What role do BRCA1 and BRCA2 mutations play in breast cancer?\nAnswer: Approximately 10% of breast cancers are due to BRCA1 or BRCA2 mutations, with lifetime risks ranging from 55% to 85% by age 70.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What did the NSABP P-1 prevention trial demonstrate regarding tamoxifen?\nAnswer: The NSABP P-1 prevention trial demonstrated that tamoxifen reduces the incidence of breast cancer by about 49% in women at high risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What are aromatase inhibitors and their role in breast cancer treatment?\nAnswer: Aromatase inhibitors, such as anastrozole and letrozole, are effective first-line treatments for hormone receptor-positive metastatic breast cancer in postmenopausal women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is the mechanism of action of fulvestrant in breast cancer treatment?\nAnswer: Fulvestrant binds to the estrogen receptor, leading to its degradation, and early studies suggest its antitumor activity is comparable to that of anastrozole.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What is the focus of treatment sequencing in metastatic breast cancer?\nAnswer: The focus is on prolongation of life and symptom improvement while minimizing toxicity.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "75b7a4f5d61c4596ac30c2a2fd35927f",
            "source": "Morrow-RecentDevelopmentsBreast-2002",
            "main_category": "Morrow"
        },
        "page_content": "Question: What recent advances have expanded treatment options for women with breast cancer?\nAnswer: Recent advances include less invasive diagnostic techniques like sentinel node biopsy and targeted endocrine therapies such as aromatase inhibitors and fulvestrant.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What is the main focus of the Empowered Wellness document?\nAnswer: The document focuses on navigating breast cancer with strength and knowledge, emphasizing the importance of early detection and awareness.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: How many women in the U.S. are estimated to be diagnosed with breast cancer in 2024?\nAnswer: Approximately 310,720 women in the United States are estimated to be diagnosed with breast cancer in 2024.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What key message does Dr. Zakia Williams-Greene convey regarding breast cancer?\nAnswer: Dr. Zakia Williams-Greene emphasizes that early detection through regular self-breast exams and annual mammograms is crucial for improving treatment success and survival rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What percentage of breast cancer cases occur in women with no family history?\nAnswer: 85% of breast cancer cases occur in women with no family history.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What role does genetic testing play for women with a family history of breast cancer?\nAnswer: Genetic testing can guide more aggressive preventive strategies, including enhanced monitoring and considering preventive surgery.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What are some holistic practices mentioned that can help manage stress for breast cancer patients?\nAnswer: Holistic practices such as meditation, yoga, and art therapy can help manage stress and empower patients.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What is the approximate accuracy rate of mammograms for early detection?\nAnswer: Mammograms have an approximate accuracy rate of 87%.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What should women do if they notice unusual changes during self-exams?\nAnswer: Women should contact their healthcare provider immediately if they notice any unusual changes during self-exams.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: At what age is it generally recommended to begin mammograms?\nAnswer: It is generally recommended to begin mammograms at age 40 or 45, with the frequency of screening increasing with age.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "a1cbab0ec15044bdbbef349b4a4b359a",
            "source": "EmpoweredWellness-2024",
            "main_category": "EmpoweredWellness"
        },
        "page_content": "Question: What resources are available for women seeking more information about breast health?\nAnswer: Women can visit www.womenofcolor.online for information and support regarding breast health and resources tailored for women of color.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What is the main objective of the study conducted by Eyler et al.?\nAnswer: The main objective of the study is to assess three state-level revenue-generating initiatives\u2014income tax check-offs, specialty license plates, and lottery tickets\u2014as methods to raise funds for breast cancer prevention, early detection, research, and education programs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: How many states had income tax check-off programs for breast cancer initiatives?\nAnswer: Eighteen states had programs allowing taxpayers to voluntarily contribute to breast cancer initiatives via income tax forms.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What was the median annual revenue generated from income tax check-offs?\nAnswer: The median annual revenue from these check-offs was approximately $115,000.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: How many states offered specialty license plates for breast cancer, and what was the total revenue generated?\nAnswer: Twenty-six states offered breast cancer specialty license plates, generating over $4.1 million in total revenue.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What was the range of additional fees for specialty license plates?\nAnswer: The additional fees for these plates ranged from $20 to $75, with a mean of $37.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: Which state provided a breast cancer-specific lottery ticket, and how much revenue did it raise?\nAnswer: Only Illinois provided a state breast cancer lottery ticket, which raised around $4 million between 2005 and 2009.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What correlation was found between breast cancer mortality rates and the availability of specialty license plates?\nAnswer: States with medium or high breast cancer mortality were about 2.5 times more likely to offer specialty license plates than states with lower mortality rates.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What factors influence the revenue generated from these initiatives?\nAnswer: The revenue amounts vary based on population differences, the range of available donation mechanisms, and economic conditions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What conclusion did the study reach regarding revenue-generating initiatives for breast cancer?\nAnswer: The study concluded that revenue-generating initiatives can be effective strategies for states to raise funds for breast cancer prevention and early detection, although the success and revenue amounts vary significantly across states.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 10,
            "id": "d2c5f5f5e70c4c3cb167523c06bb8662",
            "source": "Eyler-MethodsGeneratingState-2011",
            "main_category": "Eyler"
        },
        "page_content": "Question: What future research directions does the study suggest?\nAnswer: Future research should explore the factors influencing revenue variability and assess long-term impacts on breast cancer outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What is the main focus of the editorial from 1954?\nAnswer: The editorial discusses the early exploration of hormone treatments in breast cancer, highlighting the antagonistic biological activities of oestrogens and androgens.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What historical perspective is provided regarding the relationship between the ovary and the mammary gland?\nAnswer: Astley Cooper suggested a functional relationship between the ovary and the mammary gland in 1829, leading to the advocacy of oophorectomy as a treatment for breast cancer by 1896.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What were the findings from animal studies regarding hormonal influences on breast cancer?\nAnswer: Animal studies showed that oestrogens and androgens counteract each other, and that the removal of ovarian function reduced the incidence of breast cancer in mice.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What clinical applications of hormone treatment were discussed in the editorial?\nAnswer: Early clinical applications included the use of high doses of testosterone propionate for advanced breast carcinoma, which occasionally resulted in prolonged survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What challenges are associated with hormone treatments for breast cancer according to the editorial?\nAnswer: The editorial notes that while hormone treatments offered promising avenues, complete and sustained remission was rarely achieved, highlighting the complexity of hormonal influences.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What future directions does the editorial suggest for research in hormone treatment of breast cancer?\nAnswer: Future research should focus on better understanding steroid metabolism and the endocrine environment of breast tissue to improve treatment outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What role do the ovaries play in breast cancer according to the document?\nAnswer: The ovaries are noted to promote and maintain breast cancer growth through estrogen production, and certain tumors may be adrenal-dependent rather than ovarian-dependent.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "e4c29d8b171c4f28bac01f261317a691",
            "source": "HormoneTreatmentBreast-1954",
            "main_category": "HormoneTreatmentBreast"
        },
        "page_content": "Question: What was the overall impact of endocrine therapies based on massive doses of oestrogen?\nAnswer: Endocrine therapies based on massive doses of oestrogen were used with varying degrees of success in achieving regression of advanced breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What is the main focus of Jacques Brisson's article?\nAnswer: The article examines the relationships among family history of breast cancer in first-degree relatives, mammographic features of breast tissue, and breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: How many cases and controls were included in the study?\nAnswer: The study included 1,047 cases with newly diagnosed breast cancer and 2,329 controls.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What methods were used to assess family history and mammographic features?\nAnswer: Family history was assessed through interviews, while mammographic features were evaluated by reviewing mammograms for Wolfe's parenchymal pattern and breast density.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What was the relationship between family history and mammographic features?\nAnswer: The study found only a weak relation between family history and mammographic features among controls, indicating that family history did not significantly vary by mammographic parenchymal pattern.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What was the increase in breast cancer risk associated with family history?\nAnswer: Women with a family history of breast cancer had a 43% increase in risk compared to those without such a history.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: How did mammographic parenchymal patterns relate to breast cancer risk?\nAnswer: Different mammographic parenchymal patterns were associated with varying levels of risk, with P2 and DY patterns linked to higher risk compared to N1 and PI patterns.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What did the study conclude about the joint effects of family history and mammographic features?\nAnswer: The joint effects of family history and mammographic features on breast cancer risk appeared to be additive, suggesting that their roles in breast cancer development are largely independent.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What adjustments were made in the statistical analysis?\nAnswer: Adjustments were made for age and body weight, with a two-variable method used to account for missing weight data.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "63efd37f2d0d482ca8aa9d6ce89ef8a8",
            "source": "Brisson-FamilyHistoryBreast-1991",
            "main_category": "Brisson"
        },
        "page_content": "Question: What was the overall conclusion regarding the association of family history and mammographic features with breast cancer risk?\nAnswer: The findings indicate that while both family history and mammographic features are independently associated with breast cancer risk, there is little strong association between family history and mammographic patterns.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the main focus of the Copenhagen Consensus Center Report?\nAnswer: The report focuses on recommended interventions for screening and treatment of non-communicable diseases (NCDs) in Rajasthan, India.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What are the key health challenges identified in Rajasthan regarding NCDs?\nAnswer: Despite lower rates of overweight/obesity, Rajasthan faces low screening rates for cancers and challenges in health system capacity, quality of care, and access.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What age group is targeted for the interventions proposed in the report?\nAnswer: The interventions uniformly target individuals aged 30\u201369 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the expected impact of the cardiovascular disease (CVD) screening and treatment intervention?\nAnswer: The intervention is projected to reduce high-risk CVD deaths by approximately 20% in the 30\u201369 age group over a 13-year period.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What treatment is recommended for diabetes management in the report?\nAnswer: The report recommends routine screening for elevated blood sugar followed by treatment with Metformin for those identified with diabetes or prediabetes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: How does the report suggest addressing cervical cancer screening?\nAnswer: A screen-and-treat approach using Visual Inspection with Acetic Acid and Lugol's Iodine (VIA/VILI) is recommended for cervical cancer screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the projected outcome of the breast cancer screening intervention?\nAnswer: The intervention is projected to avert approximately 16% of breast cancer deaths.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What are the overall implications of the report's findings?\nAnswer: The report emphasizes the need for comprehensive policy planning, capacity assessments, and resource allocation to ensure effective early detection and treatment of NCDs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "51219e2bcf2447e98e57c2effc9669f4",
            "source": "Seshadri-RecommendedInterventions-2018",
            "main_category": "Seshadri"
        },
        "page_content": "Question: What is the conclusion drawn from the benefit-cost analysis for Rajasthan?\nAnswer: The analysis concludes that well-designed and efficiently delivered interventions can yield significant public health benefits, even in a state with lower risk factor levels than the national average.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What is the relationship between pregnancy and breast cancer according to the document?\nAnswer: Pregnancy and breast cancer are interconnected as some women may discover their breast cancer during pregnancy, and the timing of pregnancy can impact treatment options and outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What are the main treatment considerations for breast cancer diagnosed during pregnancy?\nAnswer: Treatment considerations include the timing of chemotherapy and radiotherapy, the potential teratogenic effects of these treatments on the fetus, and the decision to terminate the pregnancy for conventional treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What was the case study presented in the document?\nAnswer: The case study involved a 33-year-old woman who was diagnosed with high-grade invasive ductal carcinoma during pregnancy and chose to terminate her pregnancy to undergo treatment.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What are the implications of pregnancy on breast cancer prognosis?\nAnswer: Pregnancy-related increases in hormone levels may stimulate breast cancer growth, and studies suggest that the shorter the interval between birth and diagnosis, the poorer the outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What is pregnancy-associated breast cancer?\nAnswer: Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy, lactation, or up to one year postpartum, often presenting as more advanced and aggressive disease.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What are the recommendations regarding tamoxifen treatment for women considering pregnancy?\nAnswer: Women undergoing tamoxifen treatment are advised to use non-hormonal contraception and to stop tamoxifen for two months before attempting pregnancy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What resources are available for patients regarding breast cancer and pregnancy?\nAnswer: Resources include the US National Cancer Institute, the Royal College of Obstetrics and Gynaecology, and UK charities like Breastcancer.org and Breast Cancer Care.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What does the document say about the timing of chemotherapy during pregnancy?\nAnswer: The document notes that delaying chemotherapy until the second trimester may not significantly impair outcomes, as the risk of developing axillary metastasis in untreated pregnant women is low.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "13829c738c88444ba77d393943019550",
            "source": "Barthelmes-PregnancyBreastCancer-2005",
            "main_category": "Barthelmes"
        },
        "page_content": "Question: What are the social considerations for a woman diagnosed with breast cancer during pregnancy?\nAnswer: Social considerations include the potential impact on the child, the mother's health, and the possibility of the child surviving the mother in the event of recurrence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What is the main objective of the study conducted by Judy Ann Bigby and Michelle D. Holmes?\nAnswer: The main objective was to perform a structured review of the literature to identify areas of greater and lesser knowledge regarding disparities across the breast cancer continuum, from risk and prevention to treatment and mortality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What methods were used to gather data for the review on breast cancer disparities?\nAnswer: The authors searched OvidMedline and PubMed for published studies from January 1990 to March 2004 that addressed disparities in breast cancer, focusing on articles in English, limited to American populations and women, and describing quantitative outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What significant gaps in research were identified in the study?\nAnswer: The study identified gaps in knowledge regarding disparities related to sexual orientation, language, literacy, and housing, as well as limited data on other racial or ethnic minority groups beyond black and white women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What are some of the key findings regarding racial disparities in breast cancer?\nAnswer: The review found substantial research on racial disparities in breast cancer screening, diagnosis, treatment, and survival, with black women and American-Indian women showing poorer survival rates compared to Hispanic and white women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: How do socioeconomic factors influence breast cancer disparities?\nAnswer: Socioeconomic factors such as insurance status, educational attainment, and neighborhood characteristics are associated with disparities in treatment and survival outcomes in breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What is the significance of the 'cancer disparities grid' mentioned in the document?\nAnswer: The 'cancer disparities grid' serves as a visual aid to assess areas of greater or lesser knowledge regarding disparities across the cancer continuum, helping to focus policy, research, and health care interventions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What recommendations do the authors make to address breast cancer disparities?\nAnswer: The authors recommend a multidisciplinary and multi-pronged approach to translate existing research into effective interventions, which may require changes in social policy, improved understanding of cancer risk factors, and enhanced treatment strategies.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "31f2e5ada5ff42eaa8988a19a0e307f0",
            "source": "Bigby-DisparitiesacrossBreast-2005",
            "main_category": "Bigby"
        },
        "page_content": "Question: What role does racism play in breast cancer disparities according to the study?\nAnswer: Racism is noted to indirectly affect health through its influence on social structures such as education and employment, acting as a significant stressor that can impact breast cancer risk, treatment, and survival.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What is the main hypothesis presented in the document regarding iodine, selenium, and breast cancer?\nAnswer: The document hypothesizes that iodine and selenium may play a preventive role in the development of breast cancer, particularly in relation to dietary habits in Japan.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: How do iodine and selenium relate to breast cancer according to the authors?\nAnswer: Iodine is linked to the production of anti-proliferative compounds and may influence breast tissue proliferation, while selenium is essential for thyroid hormone regulation and works synergistically with iodine.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What dietary source is highlighted as rich in iodine and selenium?\nAnswer: Seaweed is highlighted as a rich dietary source of both iodine and selenium, particularly in Japan.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What evidence do the authors provide to support their hypothesis?\nAnswer: The authors reference animal and human studies showing that iodine administration can cause regression of iodine-deficient goiter and benign breast tissue, as well as epidemiological evidence linking high iodine intake to lower breast cancer incidence in Japan.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What are the authors' recommendations for future research?\nAnswer: The authors recommend conducting more rigorous retrospective and prospective studies to confirm the relationship between iodine and selenium status and breast cancer risk, including improved methods for assessing long-term iodine status.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What role does selenium play in relation to iodine and thyroid function?\nAnswer: Selenium is crucial for the proper functioning of mono-deiodinase enzymes that convert thyroid hormones, and adequate selenium levels are necessary for maintaining thyroid hormone homeostasis and optimal iodine utilization.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What differences in iodine intake are noted between Japan and other countries?\nAnswer: Japan has a very high dietary iodine intake, primarily from seaweed, with an average urinary iodine concentration around 3400 \u03bcg/L, contrasting with moderate iodine intakes in countries like the UK and USA.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "8db5b4a971a846d69c23d1b7600b098f",
            "source": "Cann-HypothesisIodineSelenium-2000",
            "main_category": "Cann"
        },
        "page_content": "Question: What potential impact does iodine deficiency have on breast tissue?\nAnswer: Iodine deficiency may increase breast tissue sensitivity to estrogen, potentially contributing to the development of breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What is the primary focus of the document?\nAnswer: The document focuses on the epidemiology, risk factors, and genetic determinants of breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What percentage of all female cancers worldwide does breast cancer account for?\nAnswer: Breast cancer accounts for approximately 18% of all female cancers worldwide.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: How does the incidence of breast cancer vary geographically?\nAnswer: Incidence and mortality rates can vary up to fivefold between countries, indicating the influence of environmental factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What are some key reproductive factors that increase breast cancer risk?\nAnswer: Key reproductive factors include early menarche, late menopause, nulliparity, and late age at first full-term pregnancy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What role do genetic factors play in breast cancer risk?\nAnswer: Genetic factors, particularly mutations in high-penetrance genes like BRCA1 and BRCA2, account for a substantial portion of hereditary breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What lifestyle factors are implicated in increasing breast cancer risk?\nAnswer: Obesity in postmenopausal women, high dietary fat intake, and alcohol consumption are lifestyle factors that increase breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What is the significance of early detection in breast cancer?\nAnswer: Early detection through screening, such as mammography, is crucial as it can reduce mortality, although it has little impact on incidence.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "f6774a5800c04ec58f7c1b452e4f58c1",
            "source": "McPherson-ABCBreastDiseases-2000",
            "main_category": "McPherson"
        },
        "page_content": "Question: What conclusion does the review draw about breast cancer?\nAnswer: The review concludes that breast cancer is a multifactorial disease influenced by genetic, hormonal, reproductive, and lifestyle factors.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What is the main focus of the article 'A Crisis of Erasure'?\nAnswer: The article examines how breast cancer health information is constructed within mainstream health and library contexts, focusing on the invisibility and erasure of transgender and gender-nonconforming (TGNC) populations.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What are the consequences of the 'crisis of erasure' for TGNC individuals?\nAnswer: The crisis of erasure creates informational boundaries, limits access, and reduces the quality of care for transgender and gender-nonconforming people who may be at risk for or are living with breast cancer.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What methodology did the authors use in their study?\nAnswer: The study involved a comprehensive literature search across multiple databases and a thematic analysis conducted by three researchers who reviewed and coded the selected literature.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What are the three key themes identified as barriers for TGNC individuals in accessing breast cancer health information?\nAnswer: The three key themes are Access, Erasure, and Quality.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What challenges do TGNC patients face in accessing health information?\nAnswer: TGNC patients face challenges such as difficulties in finding relevant information, limited appointment time with providers, and structural constraints within healthcare settings.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: How does the concept of 'erasure' affect TGNC individuals in the context of breast cancer information?\nAnswer: Erasure means that breast cancer information is largely constructed around normative ideas of femininity, marginalizing TGNC individuals and failing to reflect their experiences.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What quality concerns are raised regarding healthcare providers and librarians?\nAnswer: Quality concerns arise when providers lack cultural competency regarding transgender health, leading to TGNC patients having to educate their providers and experiencing poorer health outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What recommendations do the authors make for improving health information access for TGNC individuals?\nAnswer: The authors recommend inclusive LIS education, developing robust TGNC resources and services, and advocating for policy changes to support equitable access to health services.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "26442271c2754a969e8e6b9b9b682b58",
            "source": "Tenney-CrisisErasure-2021",
            "main_category": "Tenney"
        },
        "page_content": "Question: What is the conclusion of the article regarding the framing of breast cancer?\nAnswer: The article concludes that framing breast cancer as an exclusively female disease creates an information boundary that erases TGNC experiences, limiting access to accurate health information and negatively impacting health outcomes.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What is the focus of Part I of the clinical review on breast cancer management?\nAnswer: Part I focuses on preventive strategies, risk reduction, early detection, and improvements in local therapy, including surgery and radiotherapy.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What modifiable risk factors are linked to increased breast cancer risk?\nAnswer: Post-menopausal obesity, sedentary lifestyle, high alcohol consumption, and lower rates of breastfeeding are linked to increased breast cancer risk.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: How do Selective Oestrogen Receptor Modulators (SERMs) like tamoxifen and raloxifene contribute to breast cancer prevention?\nAnswer: Tamoxifen can reduce the incidence of invasive breast cancer by around 38% among high-risk women, while raloxifene shows a similar preventive effect in post-menopausal women.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What are the benefits and limitations of mammographic screening for breast cancer?\nAnswer: Mammographic screening can lead to a modest mortality reduction, but concerns about overdiagnosis exist.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What surgical options are discussed in the management of breast cancer?\nAnswer: Breast-conserving surgery is preferred when feasible, while mastectomy is reserved for larger tumors or patient preference. Sentinel lymph node biopsy is now standard for axillary staging.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What advancements in radiotherapy are highlighted in the review?\nAnswer: Optimized schedules, including accelerated and hypofractionated regimens, and emerging techniques like intraoperative radiotherapy and brachytherapy are discussed.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What impact have recent advances had on breast cancer mortality?\nAnswer: Improvements in screening, local management, and multimodal treatment have contributed to a decline in breast cancer mortality by over 25% in recent decades.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What practical tips are provided for non-specialists regarding breast cancer assessment?\nAnswer: Patients with potential breast abnormalities should be referred promptly to a specialist, and women with significant family histories should receive comprehensive genetic risk assessments.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "e4e2c28347a045efb600dbed600f650a",
            "source": "Turner-ManagementBreastCancer-2008",
            "main_category": "Turner"
        },
        "page_content": "Question: What future directions for breast cancer research are suggested in the review?\nAnswer: Ongoing research is needed to define optimal screening strategies, refine surgical techniques, and understand interactions between environmental risk factors and genetic predispositions.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 1,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What is the main focus of the document?\nAnswer: The document focuses on a community health worker intervention aimed at educating and navigating low-income Latina women towards receiving appropriate cancer screening tests for breast, cervical, and colorectal cancers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 2,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What percentage of all U.S. cancers do breast, cervical, and colorectal cancers account for?\nAnswer: Breast, cervical, and colorectal cancers account for 24% of all U.S. cancers.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 3,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What is the Health Belief Model (HBM) and how was it used in the intervention?\nAnswer: The Health Belief Model (HBM) posits that behavior change depends on perceived susceptibility, severity, benefits, barriers, cues to action, and self-efficacy. It was used to design the intervention to educate participants about cancer risks and encourage screening.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 4,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What were the eligibility criteria for participants in the study?\nAnswer: Participants were Latina women aged 40\u201374 who had never had a mammogram or not in the past 2 years, aged 18\u201365 with no Pap test or not in the past 3 years, and aged 50\u201375 who had never had a stool blood test or not in the past 2 years.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 5,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What were the significant knowledge gains observed after the intervention?\nAnswer: Significant improvements included knowledge of the appropriate starting age for mammograms (from 4.3% to 9.9% correct), understanding that Pap tests should be annual (72% to 80% correct), and knowledge of stool blood tests starting age and frequency (from 19% to 70% and from 42% to 75%, respectively).",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 6,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What was the outcome regarding screening behavior after the intervention?\nAnswer: Overall, 25% of eligible participants reported receiving at least one screening test (mammogram, Pap test, or stool blood test) after the intervention.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 7,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What barriers did the intervention address?\nAnswer: The intervention addressed barriers such as language, cultural challenges, and system-level issues like funding constraints at local clinics.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 8,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What implications does the study have for public health practice?\nAnswer: The study underscores the potential of community-based interventions to enhance cancer prevention efforts in underserved populations and supports the integration of community health workers in preventive health programs.",
        "type": "Document"
    },
    {
        "id": null,
        "metadata": {
            "sequence": 9,
            "id": "e980b640877b42b88aa7b400c0c80606",
            "source": "Mojica-BreastCervicalColorectal-2016",
            "main_category": "Mojica"
        },
        "page_content": "Question: What future research directions does the document suggest?\nAnswer: Future research should consider controlled designs and explore long-term impacts on cancer incidence and mortality, particularly in light of recent health reforms supporting the use of non-licensed providers like community health workers.",
        "type": "Document"
    }
]